Browse the evidence

Fewer participants received a diagnosis of type 2 diabetes in the tirzepatide groups than in the placebo group (1.3% vs. 13.3%).

Tirzepatide significantly reduces the risk of developing type 2 diabetes in individuals with obesity and prediabetes.

Three years of treatment with tirzepatide resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than that with placebo.

Tirzepatide is effective for long-term weight management and diabetes prevention.

Once-weekly subcutaneous semaglutide resulted in a mean weight change of -15.8% compared to -6.4% with once-daily subcutaneous liraglutide at 68 weeks.

Semaglutide may be more effective than liraglutide for weight loss in this population.

Participants had significantly greater odds of achieving 10% or more weight loss with semaglutide compared to liraglutide (70.9% vs 25.6%).

Semaglutide may offer a higher likelihood of significant weight loss compared to liraglutide.

Cagrilintide-semaglutide resulted in a mean percent change in body weight of -20.4% from baseline to week 68 compared to -3.0% with placebo.

Cagrilintide-semaglutide may be an effective treatment option for significant weight loss in adults with overweight or obesity.

Participants receiving cagrilintide-semaglutide were more likely to achieve weight-loss targets of 5%, 20%, 25%, and 30% or more compared to placebo.

Cagrilintide-semaglutide may help patients achieve significant weight-loss goals.

Participants receiving tirzepatide maintained a mean weight change of -5.5% from week 36 to week 88 compared to a 14.0% weight change with placebo (difference, -19.4%; P < .001).

Continued use of tirzepatide is effective for maintaining weight loss in adults with obesity.

89.5% of participants receiving tirzepatide maintained at least 80% of their weight loss during the lead-in period compared to 16.6% receiving placebo (P < .001).

Tirzepatide significantly improves the likelihood of maintaining weight loss in adults with obesity.

The overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide and 9.9% for placebo.

Tirzepatide leads to significantly greater weight loss compared to placebo over the study period.

Weekly tirzepatide 10 and 15 mg resulted in more weight loss than weekly semaglutide 2.4 mg, daily semaglutide 0.4 mg, or liraglutide 3 mg.

Tirzepatide may be a more effective option for weight loss in obese adults compared to other GLP-1RAs.

Tirzepatide and weekly semaglutide demonstrated comparable results but with significantly higher odds of achieving ≥5%–20% weight loss compared with liraglutide.

Both tirzepatide and semaglutide are viable options for achieving significant weight loss, with tirzepatide having an edge.

Daily oral orforglipron was associated with a mean weight reduction ranging from -8.6% to -12.6% at week 26 and -9.4% to -14.7% at week 36 in participants receiving the drug.

Orforglipron may be an effective oral treatment option for weight reduction in adults with obesity.

46 to 75% of participants receiving orforglipron achieved a weight reduction of at least 10% by week 36.

A significant proportion of adults with obesity may achieve clinically meaningful weight loss with orforglipron.

Calorie restriction results in a significant decrease in waist circumference of -6.1±0.4 cm compared to a control group with a change of 0.9±0.5 cm after 24 months.

Practitioners can expect significant reductions in waist circumference with CR in non-obese adults.

Once-weekly treatment with tirzepatide 10 mg resulted in a mean change in body weight of -13.6% at week 52.

Tirzepatide 10 mg can be an effective option for weight reduction in this population.

Once-weekly treatment with tirzepatide 15 mg resulted in a mean change in body weight of -17.5% at week 52.

Tirzepatide 15 mg can be an effective option for weight reduction in this population.

87.7% of participants achieved body weight reductions of 5% or greater with tirzepatide 10 mg.

A significant majority of participants experienced clinically meaningful weight loss with tirzepatide 10 mg.

In adults with obesity, treatment with 36 mg of orforglipron for 72 weeks led to a mean body weight reduction of -11.2%, significantly greater than the -2.1% reduction with placebo (P<0.001).

Orforglipron may be an effective treatment option for weight loss in obese adults.

54.6% of patients in the orforglipron 36-mg group achieved a weight reduction of 10% or more, compared to 12.9% in the placebo group.

A significant proportion of obese adults may achieve clinically meaningful weight loss with orforglipron.

Orforglipron treatment resulted in significant improvements in waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol levels compared to placebo.

Orforglipron may improve several cardiovascular and metabolic risk factors in obese adults.

All intermittent fasting and continuous energy restriction diet strategies reduced body weight when compared with ad-libitum diet.

Intermittent fasting and continuous energy restriction can be effective strategies for weight loss in diverse populations.

Alternate day fasting was the only form of intermittent fasting diet strategy to show benefit in body weight reduction compared with continuous energy restriction.

Alternate day fasting may be a more effective intermittent fasting strategy for weight loss compared to continuous energy restriction.

In comparisons between intermittent fasting strategies, alternate day fasting lowered total cholesterol, triglycerides, and non-high density lipoprotein compared with time restricted eating.

Alternate day fasting may improve lipid profiles more effectively than time restricted eating.

Oral semaglutide at a dose of 25 mg once daily resulted in a mean reduction in body weight of -13.6% from baseline to week 64.

Oral semaglutide may be an effective treatment option for weight loss in adults with obesity.